Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 96Rectal Neoplasms 45Colorectal Neoplasms 45Carcinoma, Non-Small-Cell Lung 31Esophageal Neoplasms 28Esophageal Squamous Cell Carcinoma 24Stomach Neoplasms 22Lung Neoplasms 20Pancreatic Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Colonic Neoplasms 18Neoplasms 16Sarcoma 15Adenocarcinoma Of Esophagus 15Ovarian Neoplasms 14Neoplasm Metastasis 14Head and Neck Neoplasms 14Carcinoma, Hepatocellular 14Prostatic Neoplasms 13Urinary Bladder Neoplasms 12Uterine Cervical Neoplasms 10Inflammatory Breast Neoplasms 9Fallopian Tube Neoplasms 9Osteosarcoma 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Carcinoma, Ovarian Epithelial 7Recurrence 6Multiple Myeloma 6

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Monatide (IMS 3015) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pathologic Complete Response × Neoadjuvant Therapy × Clear all
NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Tang-Du Hospital

Phase 2 Recruiting
10 enrolled
Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
600 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

NCT05441098 2022-07-01

Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology

ChineseAMS

Unknown
1,821 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡